Related references
Note: Only part of the references are listed.
Article
Oncology
Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases
M. Klinger et al.
EJSO (2009)